Comparison of Metformin and Metformin Plus Dapagliflozine for Treating Metabolic Syndrome in Patients With Poly Cystic Ovarian Syndrome (pcos)
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background: Polycystic ovarian syndrome (PCOS) is commonly associated with metabolic syndrome, including insulin resistance and obesity. This study compares the effects of Metformin alone versus Metformin plus Dapagliflozin on metabolic parameters in women with PCOS. Methods: A 12-week randomized controlled trial was conducted at Lady Willingdon Hospital, Lahore, involving 40 women with PCOS. Participants received either Metformin alone (Group A) or Metformin with Dapagliflozin (Group B). Weight, HbA1c, fasting glucose, insulin, and lipid profiles were assessed at baseline and after 12 weeks. Results: Group B showed significantly greater reductions in weight (−8.3 ± 1.1 kg vs. −2.9 ± 0.8 kg; p < 0.001) and HbA1c (−0.5% vs. −0.2%; p = 0.002). Improvements in glucose, insulin, LDL-C, HDL-C, and triglycerides were also more significant in Group B (p < 0.01). Conclusion: The combination of Metformin and Dapagliflozin was more effective than Metformin alone in improving metabolic outcomes in PCOS. It may be a promising strategy for managing metabolic syndrome in these patients.
DOI: 10.62019/6t0e3602
Authors: Shafaq Arif, Uzma Hussain, Muhaamad Essa, Maria Imran, Uswah Shoaib
Institution: King Edward Medical University
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4412048022